BOARD OF DIRECTORS
ULRIK SPORK – CHAIRMAN
Ulrik Spork is director of SporCon Lifescience Advisors and Salient Pharma, and chairman of the boards of Dansk Vækstkapital, Practio, MedTrace, ROS-Therapeutics, SOBEC Emea and Technolution. In addition, he is a member of the board of Statumanu. For many years and up until 2015, Ulrik Spork was part of executive management in Novo Holdings and served as Head of Venture Investments, Senior Partner in Novo Ventures, Managing Partner in Novo Growth Equity and most recently Managing Partner for Large Investments. He was previously a board member and chairman of the Danish Venture Capital and Private Equity Association (DVCA). Ulrik brings to Reapplix substantial knowledge of financing and business development in life science companies.
Tonni has extensive medical device and life science experience and his previous positions include being CEO of Nordic Medical Group A/S, President of ELA Medical (Canada & South America), a part of Sanofi, Global Marketing Director for St. Jude Medical (Los Angeles, USA, and Japan), BU Director for St. Jude Medical EEMEA (Brussels, Belgium), Country Manager for Guidant Nordic Area and Sales Manager for Danica Biomedical. His educational background is as a medical engineer and he holds an executive MBA from the Scandinavian International Management Institute. In Vækstfonden, he is responsible for the business development of the MedTech portfolio and has several active board memberships including Fluimedix, Advalight, TeesuVac, AnyBody Technology and FBC devices.
Klaus Eldrup-Jørgensen has an extensive career within the life science industry, with experience from big pharma, diagnostics, and biotech companies. During his 16 years in this industry, he has gained experience in areas including research and development, clinical development, sales and marketing. Moreover, he has nine years of executive management experience from Novo Nordisk, DAKO, and Nordic Bioscience. He is also the founder of several start-up companies and he holds several board positions in high-tech companies.
Today Klaus is Co-founder, majority shareholder and CEO in TrackMan A/S, a sports data and technology company founded in 2003.
Klaus Eldrup-Jørgensen has an MD from the University of Copenhagen and a B.Sc. from Copenhagen Business School.
BO JESPER HANSEN
Bo Jesper Hansen has extensive experience from orphan drug research and development, international marketing, and business development, amongst all from being CEO of Swedish Orphan Int’l from 1998-2010. Bo Jesper Hansen is and has previously been chairman and member of the board of directors in a number of biotech and pharma companies, including executive chairman of Swedish Orphan Biovitrum AB (publ), Topotarget A/S (publ), Karolinska Development AB (publ), and chairman of Ablynx NV (publ).
He is Chairman at Karo Pharma AB, Innoventa Medica ApS, Laborie Inc., and Vice-chairman of Orphazyme ApS.
Dr. Bo Jesper Hansen holds a M.D. and Ph.D. from University of Copenhagen, Denmark.
Samuel Levy, MD is the Founding Partner of the healthcare-focused asset management firm, Lauxera Capital Partners. Samuel brings deep operational experience to the growth stage healthcare products companies he backs. Samuel co-founded Allurion Technologies in 2009 and with his dedicated colleagues, advanced a swallowed and excreted gastric balloon for weight loss from the idea stage through commercialization in 33 countries. Samuel is an alumnus of Yale College (Summa Cum laude) and Harvard Medical School. He is a former McKinsey & Co. consultant and Fulbright scholar.
Søren joined Novo A/S in 2011 as Managing Investment Director of Novo Seeds. Søren obtained his MSc degree from the Technical University of Denmark in 1993 and his PhD degree in molecular biology in 1997 from the Technical University of Denmark. In addition, Søren has academic training as postdoctoral fellow at Stanford University School of Medicine. Prior to joining Novo Seeds, Søren served as global manager of Genomics at Novozymes. Before Novozymes, Søren was CSO and Vice President of R&D at Exiqon A/S. During Søren’s tenure, Exiqon completed an IPO and the company was acquired by Qiagen in 2016. Previously, Søren worked in cancer drug development as head of Lead Identification at BioImage and as research scientist at Novo Nordisk. Søren serves on the Board of Directors of EpiTherapeutics (sold to Gilead), AMRA, Biosyntia, Reapplix and Northsea Therapeutics. Since 2008, Søren has been board member of Danish Biotech (the Association of Biotechnology Industries in Denmark) and DVCA (Danish Venture Capital Association).
Cyrille Petit served as Chief Corporate Development Officer and President of Global Business Services for Smith & Nephew until 2018, and was a member of the Executive Committee from 2012. Before that, he served for 15 years with General Electric Company, where he held progressively senior Corporate Development and Strategy roles beginning with GE Capital, GE Healthcare and finally GE Transportation. He began his career in investment banking at BNP Paribas New York in 1993 and at Goldman Sachs in London between 1995 and 1997. Mr. Petit holds a Master of Arts in Finance from the HEC School of Management in Paris, France (1993).
Richard has significant experience in the medical device industry having worked for over 30 years in the field in progressively more senior roles. Starting his career in sales and marketing with first Stryker and then Biomet before becoming Managing Director of the J&J bone tissue management group responsible for the development of drug-eluting devices and biologics. He then became President of DePuy Orthopedics before moving to Align Technology where he served on the executive with responsibility for commercial operations and product development. For the last six years, he has held the position of CEO and President of Molnlycke Healthcare leaving in September 2020. He is a member of the board of Laborie Inc.
Ulrik Vejlsgaard holds an MSc. from Copenhagen Business School and an MBA from London Business School. He has extensive experience within the pharmaceutical, biotech, and medtech sectors in both operational and investment related roles. Among other, he is a Partner in North-East Healthcare, the investment vehicle of North-East Family Office for direct investments in healthcare related companies.